Skip to main content

Tables 9 Effect of δ-tocotrienol on "diseases or functions annotation" section of IPA analysis of total mRNAs of hepatitis C patients

From: δ-Tocotrienol feeding modulates gene expression of EIF2, mTOR, protein ubiquitination through multiple-signaling pathways in chronic hepatitis C patients

# Categories Diseases or Functions Annotation P-Value Predicted Activation Act Z-Score Molecules # Molecules
A Up-regulated (11)       
1 Cell Death and Survival cell death 3.94E-21 Increased 2.645 ABCD1,ABL1,ACO2 349
2 Cancer, Cell Death and Survival necrosis of malignant tumor 4.75E-21 Increased 3.412 ABL1,B2M,BCL2L11 76
3 Cellular Function and Maintenance function of lymphatic system cells 2.1E-16   0.273 ABL1,ARHGEF, 60
4 Cellular Function and Maintenance function of leukocytes 1.25E-15   0.051 ARHGEF6,ARRB2,B2M 77
5 Gene Expression, Protein Synthesis translation of mRNA 1.6E-12 Increased 2.941 BTG2,DNAJC1,EIF2S3 36
6 Gene Expression expression of mRNA 3.44E-12 Increased 2.115 BTG2,CD47,DNAJC1 43
7 Metabolic Disease glucose metabolism disorder 2.76E-08   1.558 ABHD16A,ALOX5AP,ANAPC13 136
8 Organismal Survival organismal death 0.00000495 Increased 11.544 ABL1,ADORA2A,APRT 210
9 Cancer, Hematological Disease lymphoproliferative malignancy 0.00000592   1.725 ABL1,ADORA2A,AIMP1 203
10 Neurological Disease, Organismal disorder of basal ganglia 0.0000781   1.538 ABCD1,ABL1,ADORA2A 76
11 Cancer, Organismal Injury carcinoma 0.0000854   0.711 ABCD1,ABHD16A,ABL1 749
B Down-regulated (49)      
12 Cellular Development, Cellular proliferation of immune cells 1.29E-24 Decreased -2.128 ABL1,ADORA2A,ARHGEF6 128
13 Cellular Development, Cellular proliferation of mononuclear leukocytes 6.29E-24 Decreased -2.073 ABL1,ADORA2A,ARHGEF6 123
14 Infectious Diseases Viral Infection 6.4E-24 Decreased -5.928 ABL1,ADORA2A,AGO4 207
15 Cellular Growth and Proliferation proliferation of lymphatic system cells 8.63E-24 Decreased -2.019 ABL1,ADORA2A,ARHGEF6 129
16 Immunological Disease systemic autoimmune syndrome 2.37E-23   -0.774 ABHD16A,ADORA2A,AKR1D1 163
17 Hematological System Development quantity of mononuclear leukocytes 6.64E-19 Decreased -4.691 ABL1,ADORA2A,ARHGEF6 113
18 Lymphoid Tissue Structure quantity of lymphatic system cells 1.46E-18 Decreased -4.679 ABL1,ADORA2A,ARHGEF6 115
19 Hematological System Development quantity of blood cells 6.22E-16 Decreased -4.724 ABL1,ADD3,ADORA2A 134
20 Cell-To-Cell Signaling and Interaction activation of cells 2E-15 Decreased -5.698 ADORA2A,AFP,ARRB2 127
21 Connective Tissue Disorders inflammation of joint 2.16E-13   -1.573 ABL1,ADORA2A,AKR1D1 128
22 Cardiovascular Disease, Developmental Diamond-Blackfan anemia 4.55E-11    CD52,FLVCR1,RPL11 13
23 Antimicrobial Response, Inflammatory antimicrobial response 8.55E-09   -1.395 APOBEC3A,ATG5,BCL10 44
24 Embryonic Development, Hematological formation of lymphoid tissue 1.45E-08 Decreased -2.618 ABL1,B2M,BCL2L11 48
25 Free Radical Scavenging metabolism of reactive oxygen species 1.56E-08 Decreased -2.89 ABL1,ATG5,ATP7A 63
26 Neurological Disease, Skeletal neuromuscular disease 5.12E-07   -0.200 ABL1,ADORA2A,ALAS1 95
27 Cell Morphology morphology of blood cells 7.37E-07    ABCD1,ABL1,ADD3 52
28 Inflammatory Response, Neurological inflammation of central nervous system 0.00000109   -1.099 ADORA2A,B2M,C3AR1 48
29 Humoral Immune Response, Protein production of antibody 0.00000114   -1.497 B2M,BCL10,BCL2L11 40
30 Endocrine System Disorders diabetes mellitus 0.00000166 Decreased -2.058 ABHD16A,ALOX5AP,ANAPC13 110
31 Digestive System Development morphology of Peyer's patches 0.00000208    DDX58,ID2,IGKC 12
32 Cellular Compromise, Inflammatory degranulation of cells 0.0000021 Decreased -3.08 C3AR1,C5AR1,CAMP 31
33 Cell Signaling, Molecular Transport mobilization of Ca2+ 0.00000212 Decreased -2.95 ADORA2A,ARRB2,B2M 42
34 Cell-To-Cell Signaling and Interaction binding of leukocytes 0.00000273 Decreased -4.799 ABL1,ADORA2A,ARRB2 46
35 Immunological Disease allergy 0.00000286   -1.655 ABL1,ACO2,ADORA2A 49
36 Humoral Immune Response, Protein quantity of immunoglobulin 0.00000494   -1.731 B2M,BCL10,BCL2L11 37
37 RNA Post-Transcriptional Modification processing of RNA 0.0000059   -0.670 ADAT1,AFF2,CELF1 36
38 Hematological System Development quantity of thymocytes 0.00000592 Decreased -3.599 ABL1,B2M,BCL10 30
39 Immunological Disease abnormal morphology of immune 0.00000593    ABCD1,ABL1,B2M 37
40 Cancer, Hematological Disease mature B-cell lymphoma 0.00000888    ABL1,B2M,BCL10 38
41 Digestive System Development abnormal morphology of Peyer's 0.00000906    DDX58,ID2,IGKC 11
42 Lipid Metabolism, Small Molecule synthesis of eicosanoid 0.00000989 Decreased -3.209 ALOX5AP,ATP5J,C5AR1 29
43 Cellular Growth and Proliferation expansion of cells 0.0000113   -0.717 ADORA2A,B2M,BMI1 37
44 Lipid Metabolism, Small Molecule synthesis of leukotriene C4 0.0000148 Decreased -2.753 ALOX5AP,C5AR1,COTL1 8
45 Gene Expression activation of DNA endogenous 0.000016 Decreased -3.846 ARRB2,ATF4,BMI1 111
46 Antigen Presentation, Inflammatory antigen presentation 0.0000715   -1.556 ARL8B,CD74,CST3 14
47 Cell Death and Survival, Organismal cell death of kidney cells 0.0000715   -1.863 ATG5,ATP1A1,BCL10 39
48 Cellular Movement, Hematological chemotaxis of granulocytes 0.0000723 Decreased -2.235 ADORA2A,BST1,C3AR1 24
49 Cancer, Hematological Disease large-cell lymphoma 0.0000741    B2M,BCL2L11,CAMLG 34
50 Cell-To-Cell Signaling and Interaction binding of mononuclear leukocytes 0.0000753 Decreased -3.212 CD47,CD48,CD58 25
51 Cellular Movement, Embryonic chemotaxis of embryonic cell lines 0.0000767 Decreased -2.587 ARRB2,CAMP,CXCL1 7
52 Cellular Movement, Hair and Skin chemotaxis of epithelial cell lines 0.0000767 Decreased -2.587 ARRB2,CAMP,CXCL1 7
53 Cell Death and Survival, Skeletal cell death of smooth muscle cells 0.0000775   -0.332 ARRB2,CAMP,CASP3 16
54 Cell Death and Survival cell viability of phagocytes 0.0000775 Decreased -2.939 BCL2A1,CD48,CEBPB 16
55 Cell Death and Survival killing of lymphatic system cells 0.0000789 Decreased -2.016 BCL2L11,CD47,CD48 10
56 Cell Death and Survival cell viability of mononuclear leukocytes 0.0000805 Decreased -3.491 ATG3,BCL10,BCL2L11 25
57 Cellular Development, Cellular Growth differentiation of myeloid leukocytes 0.0000809   -1.081 ABL1,CAMP,CD47 31
58 Cell-To-Cell Signaling and Interaction binding of lymphatic system cells 0.0000847 Decreased -3.360 CD47,CD48,CD58 23
59 RNA Post-Transcriptional Modification unwinding of mRNA 0.000086    EIF4A1,EIF4A2,EIF4B 3
60 Cell Death and Survival, Organismal cell death of epithelial cells 0.000136   -1.105 ARRB2,ATG5,BCL10 51